Update on Kinase Inhibitors for CLL: Where Are We Now?
Kinase inhibitors, a newer approach to fighting blood cancers, have been making major strides throughout 2011 for the treatment of CLL. Dr. Susan O'Brien, an investigator of this approach, gives us an update on the ongoing trials for CAL-101 and PCI-32765. She explains how they are not only very effective at fighting the CLL and can be taken orally, but how kinase inhibitors carry lower toxicity which allows them to be better tolerated, especially by older patients. Additionally, these drugs do not cause myelosuppression--the reduction of desirable cells in the blood--that is associated with chemotherapy treatment.
Experts & Guests
Susan M. O'Brien, MD
Professor, Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer CenterSusan M. O’Brien, M.D., is a professor in the department of leukemia and clinical consultant and special assistant to the physician-in-chief at MD Anderson Cancer Center. Dr. O’Brien received her medical degree from the University of Medicine and Dentistry of New Jersey in Newark. She went on to complete a residency in internal medicine at the University of Medicine and Dentistry of... more >